Resveratrol: History and Discovery

Most people first heard of resveratrol as "the molecule in red wine" — the supposed reason the French could eat rich food and still have healthy hearts. The real story is older, quieter, and more interesting than that headline. Resveratrol was first described by a Japanese researcher in 1939, isolated not from grapes but from the root of the white hellebore, and it sat in the scientific literature for decades as a chemical curiosity. Only in 1976 was it shown to be a defensive compound that grapevines make when attacked, only in 1992 was it measured in wine and tied to the "French paradox," and only in 1997 and 2003 did two landmark papers — one on cancer prevention, one on yeast lifespan — turn it into one of the most studied and most argued-over molecules in modern nutrition science. This article follows that thread, naming the real researchers and dates where the record is firm and flagging clearly where it is contested or uncertain.

Table of Contents

  1. A Molecule from White Hellebore (1939)
  2. Where the Name Comes From
  3. The Knotweed Connection (1963)
  4. The Grapevine Phytoalexin (1976)
  5. Wine, the French Paradox, and the Leap to Fame (1992)
  6. The 1997 Cancer Paper That Changed Everything
  7. Sirtuins, Lifespan, and Controversy (2003 onward)
  8. What the History Leaves Us With
  9. Research Papers and References
  10. Connections
  11. Featured Videos

A Molecule from White Hellebore (1939)

Resveratrol's documented history begins not in a vineyard but in a study of traditional medicinal plants. The compound was first described by the Japanese researcher Michio Takaoka, who isolated it from the root of the white hellebore, Veratrum grandiflorum (a plant also classed as Veratrum album variety grandiflorum). The earliest mention of the substance is generally dated to 1939, with Takaoka's fuller account of the isolation appearing in work published around 1940. Sources differ on which of those two years to attach to the "discovery," so the honest way to state it is that resveratrol was first described by Takaoka at the very end of the 1930s.

It is worth being clear about what Takaoka did and did not do. He isolated and named a specific chemical compound from a plant with a folk reputation as a medicine; he did not discover red wine's health effects, sirtuins, or anything resembling the longevity claims that would come later. White hellebore is a toxic plant, and Takaoka's interest was the natural-products chemistry of a traditional remedy, not a search for a dietary supplement. For its first quarter-century, resveratrol was essentially an obscure entry in the chemistry literature — a named molecule waiting for a reason to matter.

Back to Table of Contents

Where the Name Comes From

The word resveratrol is not arbitrary; it is a small piece of chemical bookkeeping built from the compound's structure and its source. The widely repeated explanation is that the name combines three elements: res- from resorcinol (a benzene ring carrying two hydroxyl groups, a fragment that appears in resveratrol's molecular skeleton), -veratr- from the genus Veratrum (the white hellebore it was isolated from), and the ending -ol, the standard chemical suffix marking an alcohol — that is, a molecule bearing hydroxyl (–OH) groups. In plain terms: a resorcinol-type compound, from a Veratrum species, that is an alcohol.

This etymology is the one given in the standard reviews of the molecule, and it lines up neatly with resveratrol's formal chemical name, 3,5,4′-trihydroxy-trans-stilbene — a stilbene backbone carrying three hydroxyl groups. The name is a useful reminder of where the molecule came from: the public knows it as a grape and wine compound, but its very name still points back to the hellebore root on a chemist's bench in the 1930s.

Back to Table of Contents

The Knotweed Connection (1963)

The next milestone is the one most directly relevant to anyone who has ever swallowed a resveratrol capsule. In 1963, resveratrol was isolated from the roots of Japanese knotweed (Polygonum cuspidatum, also classified as Reynoutria japonica or Fallopia japonica) — a plant long used in traditional East Asian medicine, where the root is known as Hu Zhang. Knotweed root turned out to be an exceptionally rich source of the compound, far richer than grapes, and this is the historical reason that essentially every resveratrol supplement sold today is extracted from knotweed rather than from wine or grapes.

This connection threads resveratrol back into a documented herbal tradition that long predates its Western fame. The molecule did not arrive out of nowhere in the wine aisle; it was already present in plants people had been using medicinally for centuries, even though no one before the twentieth century could have named the specific compound responsible. The fuller traditional and botanical story of the source plant is told on the dedicated Japanese Knotweed page; for the history of resveratrol itself, the key point is that 1963 is when the molecule and its future commercial source were joined.

Back to Table of Contents

The Grapevine Phytoalexin (1976)

The discovery that reframed resveratrol from chemical curiosity into a biologically meaningful molecule came in 1976, when the plant pathologists Philip Langcake and R. J. Pryce published a study titled "The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury" in the journal Physiological Plant Pathology. Working with grapevine leaves, they showed that healthy tissue contained essentially no resveratrol, but that infected or ultraviolet-irradiated leaves accumulated it — identifying it as the compound responsible for the blue fluorescence of stressed grapevine tissue.

This established resveratrol as a phytoalexin: a defensive compound a plant manufactures on demand when it is wounded, irradiated, or attacked by fungi — notably Botrytis cinerea, the grey mould of grapes. That single insight explains a great deal of what came after. It is why grapes grown in cool, damp, fungus-pressured climates tend to be richer in resveratrol; it is the mechanistic basis for the later idea that the molecule is a "stress signal"; and it is the reason resveratrol is concentrated in grape skins, the plant's front line of defence. Langcake and Pryce did not make any health claim — their work was botany, not medicine — but by showing that grapevines make resveratrol in response to stress, they built the bridge that the wine story would soon cross.

Back to Table of Contents

Wine, the French Paradox, and the Leap to Fame (1992)

If 1976 made resveratrol scientifically interesting, 1992 made it famous. Two things happened that year. First, the researchers E. H. Siemann and L. L. Creasy published "Concentration of the Phytoalexin Resveratrol in Wine" in the American Journal of Enology and Viticulture, measuring how much resveratrol was actually present in wines and showing that red wine, fermented in contact with the grape skins, carried meaningfully more than white. For the first time, the defensive molecule of the grapevine had been put on a scale inside a glass of wine.

Second, and far more visible to the public, was the "French paradox." In a 1992 commentary in The Lancet titled "Wine, alcohol, platelets, and the French paradox for coronary heart disease," the French researchers Serge Renaud and Michel de Lorgeril highlighted the puzzle that French populations had relatively low rates of coronary heart disease despite a diet high in saturated fat, and proposed that habitual moderate wine drinking was part of the explanation. Resveratrol — a distinctive polyphenol of red wine that had just been quantified and was already known to be biologically active in plants — quickly became the headline candidate molecule in the popular retelling.

Honesty matters here, because this is where myth and evidence parted ways. Renaud and de Lorgeril's own argument emphasised alcohol's effects on blood platelets, not resveratrol specifically, and the paradox itself is at least as plausibly explained by the overall Mediterranean dietary pattern, the ethanol, and confounding lifestyle factors. The amount of resveratrol in even heavy wine consumption is far too small to plausibly drive a cardiovascular effect on its own. The accurate historical statement is this: the French paradox is how resveratrol entered public consciousness, not proof that resveratrol explains the paradox. That distinction has been muddied in marketing ever since.

Back to Table of Contents

The 1997 Cancer Paper That Changed Everything

For all the wine publicity, resveratrol's transformation into a serious research subject is usually traced to a single, specific paper. In 1997, a team led by Meishiang Jang, working in the laboratory of John M. Pezzuto at the University of Illinois at Chicago, published "Cancer chemopreventive activity of resveratrol, a natural product derived from grapes" in the journal Science. The paper reported that purified resveratrol showed activity against laboratory models representing all three major stages of cancer development — acting as an antioxidant and antimutagen, dampening inflammation through effects on the cyclooxygenase enzyme, and prompting leukaemia cells to differentiate.

The effect of this paper on the scientific community is hard to overstate. Before 1997, resveratrol generated only sporadic, scattered reports; afterwards, publications on the molecule climbed steeply, and it became one of the most intensively studied natural products in the world. It is important to read the 1997 result for what it actually was — promising activity in cell and animal model systems, not a demonstration that resveratrol prevents cancer in people — but as a historical turning point it is unambiguous: this was the moment resveratrol stopped being a wine curiosity and became a mainstream target of biomedical research.

Back to Table of Contents

Sirtuins, Lifespan, and Controversy (2003 onward)

The final chapter of resveratrol's rise is also its most contested. In 2003, a paper in Nature from a group including Konrad Howitz and David Sinclair reported that resveratrol was the most potent of a set of small molecules that activated SIRT1 — a so-called sirtuin enzyme tied to the biology of caloric restriction — and that it extended the replicative lifespan of budding yeast. Further reports followed of lifespan extension in worms, fruit flies, and short-lived fish, and then, most influentially, a 2006 Nature paper led by Joseph Baur and colleagues showing that resveratrol improved the health and survival of mice fed a high-calorie diet, shifting their physiology toward that of leaner, healthier animals. Resveratrol was now being described as a possible caloric-restriction mimetic — a compound that might reproduce some benefits of eating less without eating less.

This is where the story acquired real baggage, and a fair history has to say so plainly. The commercial stakes rose fast: Sinclair co-founded Sirtris Pharmaceuticals in 2004 to develop sirtuin-activating compounds, and GlaxoSmithKline acquired the company in 2008 for roughly 720 million dollars. The science then came under sustained challenge. The laboratory assay used to show that resveratrol "directly" switches on SIRT1 was found to depend on an artificial fluorescent tag attached to the test molecule; when scientists at Pfizer, Amgen, and elsewhere removed that artefact, the clean direct-activation effect largely vanished, suggesting resveratrol's influence on SIRT1 in living cells is mostly indirect. GlaxoSmithKline shut down the Sirtris operation in 2013. Separately — and distinct from Sinclair's work — a different resveratrol researcher, Dipak Das at the University of Connecticut, was found in 2012 to have fabricated data, leading to many retractions; the two affairs became conflated in the public mind and deepened the cloud of scepticism over the whole field.

The careful conclusion drawn by the field today is genuinely mixed rather than triumphant or dismissive. Resveratrol almost certainly does engage sirtuin and energy-sensing signalling, but probably indirectly; the lifespan benefits are real in some stressed animal models but were over-sold; and a demonstrated human lifespan effect has never been shown. The detailed mechanism, the clinical-trial record, and the dosing and safety picture are covered on the main Resveratrol page. This history's job is only to record how the molecule travelled from a hellebore root to the centre of the longevity debate — and how much of that journey rests on claims that later had to be qualified.

Back to Table of Contents

What the History Leaves Us With

Read as a whole, resveratrol's history is a useful case study in how a molecule becomes famous. A toxic medicinal plant gave up a named compound in 1939; that compound sat ignored for decades; a piece of plant pathology in 1976 revealed why it exists at all; a wine measurement and a cardiology commentary in 1992 handed it a memorable public story; a 1997 cancer paper made it a serious research subject; and a 2003 lifespan finding turned it into a longevity icon whose foundations were then partly knocked out from under it. At no point does the historical record support the simplest popular version — "drink red wine, live longer, because of resveratrol."

What the history does support is more modest and more honest: resveratrol is a real, well-characterised plant defence molecule with genuine biological activity, a strong mechanistic rationale, and a clinical record that is promising in places and disappointing in others. It is one of the most studied natural compounds in the world precisely because each of these chapters generated more questions than it answered. Knowing where the molecule came from — and which famous claims about it were later qualified or retracted — is the best defence against the marketing that still surrounds it.

Back to Table of Contents

Research Papers and References

The list below gathers the landmark papers that mark resveratrol's documented history, followed by curated PubMed topic-search links. Author names, titles, and journals are given as plain text; only a stable DOI, PMID, or archival link is hyperlinked, and each opens in a new tab. The earliest milestone — Takaoka's 1939–1940 isolation from Veratrum grandiflorum — predates modern indexing and carries no DOI or PMID, so it is cited here as a historical source by author, title, journal, and year.

  1. Takaoka M. Resveratrol, a new phenolic compound from Veratrum grandiflorum. Journal of the Faculty of Science, Hokkaido Imperial University. 1940 (first described 1939). — Historical primary source; named here by author, title, journal, and year (predates PubMed; no DOI/PMID).
  2. Langcake P, Pryce RJ. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiological Plant Pathology. 1976;9(1):77–86. — doi:10.1016/0048-4059(76)90077-1
  3. Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. American Journal of Enology and Viticulture. 1992;43(1):49–52. — doi:10.5344/ajev.1992.43.1.49 (historical enology source; predates PubMed indexing).
  4. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. The Lancet. 1992;339(8808):1523–1526. — PMID: 1351198
  5. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275(5297):218–220. — doi:10.1126/science.275.5297.218 · PMID: 8985016
  6. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191–196. — doi:10.1038/nature01960
  7. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337–342. — doi:10.1038/nature05354

Live PubMed Searches

  1. Resveratrol history & discovery
  2. Resveratrol & the French paradox

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents